This is a Validated Antibody Database (VAD) review about human CD133, based on 87 published articles (read how Labome selects the articles), using CD133 antibody in all methods. It is aimed to help Labome visitors find the most suited CD133 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
CD133 synonym: AC133; CD133; CORD12; MCDR2; MSTP061; PROML1; RP41; STGD4

Miltenyi Biotec
mouse monoclonal (AC133)
  • flow cytometry; human; loading ...; fig 6f
Miltenyi Biotec CD133 antibody (Miltenyi, 130-113-108) was used in flow cytometry on human samples (fig 6f). iScience (2022) ncbi
mouse monoclonal (W6B3C1)
  • immunohistochemistry; mouse; 1:40; fig s3
Miltenyi Biotec CD133 antibody (Miltenyi Biotec, W6B3C1) was used in immunohistochemistry on mouse samples at 1:40 (fig s3). Sci Rep (2021) ncbi
mouse monoclonal (293C3)
  • flow cytometry; human; loading ...; fig 4b
Miltenyi Biotec CD133 antibody (Miltenyi Biotec, 293C3) was used in flow cytometry on human samples (fig 4b). EMBO Mol Med (2021) ncbi
mouse monoclonal (AC133)
  • other; human; 1:50; loading ...
Miltenyi Biotec CD133 antibody (Miltenyi Biotech, AC133) was used in other on human samples at 1:50. elife (2020) ncbi
mouse monoclonal (293C3)
  • flow cytometry; human; 1:500; loading ...; fig s2d
Miltenyi Biotec CD133 antibody (Miltenyi Biotech, 130-090-854) was used in flow cytometry on human samples at 1:500 (fig s2d). Stem Cell Reports (2020) ncbi
mouse monoclonal (293C3)
  • flow cytometry; human; fig 1f
Miltenyi Biotec CD133 antibody (Miltenyi, 130-090-851) was used in flow cytometry on human samples (fig 1f). Oncogene (2020) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human; 1:11; loading ...; fig 2d
Miltenyi Biotec CD133 antibody (Miltenyi Biotech, AC133) was used in flow cytometry on human samples at 1:11 (fig 2d). elife (2019) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human; loading ...; fig 4
Miltenyi Biotec CD133 antibody (Miltenyi Biotech, AC133) was used in flow cytometry on human samples (fig 4). Biol Open (2019) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human; loading ...; fig 1b
Miltenyi Biotec CD133 antibody (Miltenyi Biotech, 130-113-668) was used in flow cytometry on human samples (fig 1b). Theranostics (2019) ncbi
mouse monoclonal (AC141)
  • immunohistochemistry; human; loading ...; fig 2h
Miltenyi Biotec CD133 antibody (Miltenyi Biotec, 130-090-423) was used in immunohistochemistry on human samples (fig 2h). Cancer Res (2018) ncbi
mouse monoclonal (W6B3C1)
  • immunohistochemistry - frozen section; human; 1:50; loading ...; fig 4b
Miltenyi Biotec CD133 antibody (Miltenyi Biotech, 130-092-395) was used in immunohistochemistry - frozen section on human samples at 1:50 (fig 4b). J Histochem Cytochem (2018) ncbi
mouse monoclonal (AC133)
  • immunocytochemistry; human; loading ...; fig 2a
Miltenyi Biotec CD133 antibody (Miltenyi, AC133) was used in immunocytochemistry on human samples (fig 2a). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (293C3)
  • immunohistochemistry; human; loading ...; fig 6c
In order to test if MUC1 contributes to epithelial tubular cell plasticity and kidney fibrosis, Miltenyi Biotec CD133 antibody (MACS Milteny Biotec, 130-090-851) was used in immunohistochemistry on human samples (fig 6c). Biochim Biophys Acta Mol Basis Dis (2017) ncbi
mouse monoclonal (293C3)
  • mass cytometry; human; fig s8
Miltenyi Biotec CD133 antibody (Miltenyi, 130-090-851) was used in mass cytometry on human samples (fig s8). Nature (2017) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human; loading ...; fig 4b
Miltenyi Biotec CD133 antibody (Miltenyi Biotec, AC133) was used in flow cytometry on human samples (fig 4b). Int J Mol Sci (2017) ncbi
mouse monoclonal (W6B3C1)
  • western blot; human; loading ...; fig 2a
Miltenyi Biotec CD133 antibody (Miltenyi, W6B3C1) was used in western blot on human samples (fig 2a). Mol Oncol (2017) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human; tbl 3
In order to document and describe lymphocyte predominant cells from lymph nodes involved in nodular lymphocyte predominant Hodgkin lymphoma, Miltenyi Biotec CD133 antibody (Miltenyi Biotec, AC133) was used in flow cytometry on human samples (tbl 3). Am J Pathol (2017) ncbi
mouse monoclonal (AC133)
  • western blot; human; loading ...; fig 2d
  • immunocytochemistry; mouse; loading ...; fig 1b
  • western blot; rat; loading ...; fig 3c
Miltenyi Biotec CD133 antibody (Miltenyi, AC133) was used in western blot on human samples (fig 2d), in immunocytochemistry on mouse samples (fig 1b) and in western blot on rat samples (fig 3c). Oncotarget (2016) ncbi
mouse monoclonal (AC141)
  • immunocytochemistry; human; 1:50; fig 2
In order to investigate the contribution of DNA methyltransferase 1 to the epithelial-mesenchymal transition and cancer stem cells, Miltenyi Biotec CD133 antibody (Miltenyi Biotec, 130-090-423) was used in immunocytochemistry on human samples at 1:50 (fig 2). Neoplasia (2016) ncbi
mouse monoclonal (W6B3C1)
  • flow cytometry; human; fig s1b
  • western blot; human; fig s1d
Miltenyi Biotec CD133 antibody (Miltenyi Biotec, 130-092-395) was used in flow cytometry on human samples (fig s1b) and in western blot on human samples (fig s1d). Oncotarget (2016) ncbi
mouse monoclonal (AC133)
  • immunohistochemistry; human; 1:25; fig 1c
In order to study CD133+ subpopulations in pancreatic cancer, Miltenyi Biotec CD133 antibody (Miltenyi Biotec, AC133) was used in immunohistochemistry on human samples at 1:25 (fig 1c). Oncol Lett (2016) ncbi
mouse monoclonal (W6B3C1)
  • western blot; human; 1:150; loading ...; fig 12b
Miltenyi Biotec CD133 antibody (Macs, W6B3C1) was used in western blot on human samples at 1:150 (fig 12b). Oncotarget (2016) ncbi
mouse monoclonal (W6B3C1)
  • immunohistochemistry - paraffin section; human; fig 1
In order to study tumor periphery glioma cells and their stem cell phenotype, Miltenyi Biotec CD133 antibody (Miltenyi Biotec, W6B3C1) was used in immunohistochemistry - paraffin section on human samples (fig 1). PLoS ONE (2016) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human; fig s1
Miltenyi Biotec CD133 antibody (Miltenyi, AC133) was used in flow cytometry on human samples (fig s1). PLoS ONE (2016) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human; 1:40; fig 1a
Miltenyi Biotec CD133 antibody (Miltenyi Biotec, AC133) was used in flow cytometry on human samples at 1:40 (fig 1a). PLoS ONE (2016) ncbi
mouse monoclonal (AC141)
  • immunocytochemistry; human; fig 3
Miltenyi Biotec CD133 antibody (Miltenyi Biotec, 130-090-423) was used in immunocytochemistry on human samples (fig 3). Oncotarget (2016) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human; fig 3
Miltenyi Biotec CD133 antibody (Miltenyi Biotec, AC133) was used in flow cytometry on human samples (fig 3). Sci Rep (2016) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human; 1:100; fig 1
Miltenyi Biotec CD133 antibody (Miltenyi Biotec, AC133/1) was used in flow cytometry on human samples at 1:100 (fig 1). PLoS ONE (2015) ncbi
mouse monoclonal (AC133)
  • immunohistochemistry - paraffin section; human; 1:100; fig 4
In order to determine the regeneration-associated stem cell-related phenotype of hepatocyte-derived growth factor receptor-expressing cells in active ulcerative colitis, Miltenyi Biotec CD133 antibody (Miltenyi, Clone: AC133) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 4). World J Gastroenterol (2015) ncbi
mouse monoclonal (AC133)
  • immunohistochemistry - paraffin section; mouse; 1:20; fig 3
In order to characterize a conditional knock out of ataxia telangiectasia-mutated as a mouse model of pancreatic ductal adenocarcinoma, Miltenyi Biotec CD133 antibody (Miltenyl Biotec, 130-090-422) was used in immunohistochemistry - paraffin section on mouse samples at 1:20 (fig 3). Nat Commun (2015) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human; fig 1
Miltenyi Biotec CD133 antibody (Miltenyi Biotech, AC133) was used in flow cytometry on human samples (fig 1). Oncotarget (2015) ncbi
mouse monoclonal (AC133)
  • immunohistochemistry - paraffin section; human; 1:100; fig 4
  • flow cytometry; human; fig 1b
Miltenyi Biotec CD133 antibody (Miltenyi Biotec, AC133) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 4) and in flow cytometry on human samples (fig 1b). Sci Rep (2015) ncbi
mouse monoclonal (AC133)
  • immunocytochemistry; human; 1:4; fig 1
Miltenyi Biotec CD133 antibody (Miltenyi Biotec, 130-090-422) was used in immunocytochemistry on human samples at 1:4 (fig 1). Int J Mol Med (2015) ncbi
mouse monoclonal (AC133)
  • western blot; human
In order to discuss methods and reagents used to examine endothelial cells by flow cytometry, Miltenyi Biotec CD133 antibody (Miltenyi Biotec, AC133) was used in western blot on human samples . Rev Bras Hematol Hemoter (2015) ncbi
mouse monoclonal (W6B3C1)
  • western blot; human; fig s1
Miltenyi Biotec CD133 antibody (Miltenyi, W6B3C1) was used in western blot on human samples (fig s1). PLoS ONE (2014) ncbi
mouse monoclonal (AC133)
  • immunohistochemistry - paraffin section; human; 1:50
  • immunocytochemistry; human; 1:50
Miltenyi Biotec CD133 antibody (Miltenyi, 130-090-422) was used in immunohistochemistry - paraffin section on human samples at 1:50 and in immunocytochemistry on human samples at 1:50. Cell Death Dis (2014) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human
Miltenyi Biotec CD133 antibody (Miltenyi Biotec, AC133) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (AC133)
  • flow cytometry; mouse; 1:20
Miltenyi Biotec CD133 antibody (Miltenyi, AC133) was used in flow cytometry on mouse samples at 1:20. PLoS ONE (2014) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human
In order to generate and assess primary pancreatic adenocarcinoma cell lines for colony forming capacity, tumourigenicity, expression of known cancer cell surface markers and cancer stem-like characteristics, Miltenyi Biotec CD133 antibody (Miltenyi, clone AC133) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human; 1:10
Miltenyi Biotec CD133 antibody (MACS, AC133) was used in flow cytometry on human samples at 1:10. Cancer Res (2014) ncbi
mouse monoclonal (W6B3C1)
  • western blot; human; fig 5
Miltenyi Biotec CD133 antibody (Miltenyi biotech, W6B3C1) was used in western blot on human samples (fig 5). PLoS ONE (2014) ncbi
mouse monoclonal (W6B3C1)
  • immunohistochemistry; human
Miltenyi Biotec CD133 antibody (Miltenyi Biotec, W6B3C1) was used in immunohistochemistry on human samples . Oncogene (2015) ncbi
mouse monoclonal (W6B3C1)
  • western blot; human
In order to investigate the role of TMPRSS4 in colorectal cancer, Miltenyi Biotec CD133 antibody (Miltenyi Biotec, 130-092-395) was used in western blot on human samples . Cancer Biol Ther (2014) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human; loading ...; fig s8
Miltenyi Biotec CD133 antibody (Miltenyi Biotech, AC133) was used in flow cytometry on human samples (fig s8). Int J Cancer (2014) ncbi
mouse monoclonal (AC133)
  • flow cytometry; human; fig 1
Miltenyi Biotec CD133 antibody (Miltenyi, AC133) was used in flow cytometry on human samples (fig 1). J Tissue Eng Regen Med (2015) ncbi
BioLegend
mouse monoclonal (7)
  • mass cytometry; human; loading ...; fig 4a
BioLegend CD133 antibody (Biolegend, 372802) was used in mass cytometry on human samples (fig 4a). Cell Rep (2022) ncbi
mouse monoclonal (7)
  • western blot; human; loading ...; fig 4b
BioLegend CD133 antibody (Biolegend, 372802) was used in western blot on human samples (fig 4b). MAbs (2021) ncbi
mouse monoclonal (7)
  • mass cytometry; human; 1:50; loading ...; fig s2
BioLegend CD133 antibody (Biolegend, clone 7) was used in mass cytometry on human samples at 1:50 (fig s2). Int J Mol Sci (2021) ncbi
mouse monoclonal (7)
  • flow cytometry; human; 4:100; loading ...; fig 1a
BioLegend CD133 antibody (Biolegend, clone 7) was used in flow cytometry on human samples at 4:100 (fig 1a). elife (2021) ncbi
mouse monoclonal (7)
  • flow cytometry; human; loading ...; fig 4a
BioLegend CD133 antibody (Biolegend, 372804) was used in flow cytometry on human samples (fig 4a). Cell Commun Signal (2020) ncbi
mouse monoclonal (7)
  • flow cytometry; mouse; 1:100; loading ...; fig s20e
BioLegend CD133 antibody (Biolegend, 372810) was used in flow cytometry on mouse samples at 1:100 (fig s20e). Nat Commun (2020) ncbi
mouse monoclonal (7)
  • flow cytometry; human; loading ...; fig 2a
BioLegend CD133 antibody (BioLegend, 7) was used in flow cytometry on human samples (fig 2a). Int J Mol Sci (2018) ncbi
Abcam
domestic rabbit polyclonal
  • flow cytometry; human; 1:200; fig s3
  • immunocytochemistry; human; 1:200; fig s2
Abcam CD133 antibody (Abcam, ab19898) was used in flow cytometry on human samples at 1:200 (fig s3) and in immunocytochemistry on human samples at 1:200 (fig s2). BMC Cancer (2022) ncbi
domestic rabbit monoclonal (EPR20980-104)
  • western blot; human; loading ...; fig 4b
Abcam CD133 antibody (Abcam, ab216323) was used in western blot on human samples (fig 4b). Thorac Cancer (2022) ncbi
domestic rabbit polyclonal
  • western blot; human; 1:1000; loading ...; fig 2f
Abcam CD133 antibody (Abcam, Ab19898) was used in western blot on human samples at 1:1000 (fig 2f). NPJ Breast Cancer (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; loading ...; fig s1
Abcam CD133 antibody (ABCAM, ab19898) was used in immunohistochemistry - paraffin section on human samples (fig s1). Adv Sci (Weinh) (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 6e
Abcam CD133 antibody (Abcam, ab19898) was used in immunohistochemistry - paraffin section on mouse samples (fig 6e). Front Oncol (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; 1:200; loading ...; fig 3a
Abcam CD133 antibody (Abcam, ab19898) was used in immunohistochemistry - paraffin section on mouse samples at 1:200 (fig 3a). Sci Adv (2021) ncbi
domestic rabbit polyclonal
  • flow cytometry; human; loading ...; fig 2c, 2d
Abcam CD133 antibody (Abcam, ab19898) was used in flow cytometry on human samples (fig 2c, 2d). Front Oncol (2020) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 6b
Abcam CD133 antibody (Abcam, ab19898) was used in western blot on human samples (fig 6b). Cancer Cell Int (2019) ncbi
Abnova
domestic rabbit polyclonal
  • western blot; mouse; 1:1000; loading ...; fig 3a
Abnova CD133 antibody (Abnova, PAB12663) was used in western blot on mouse samples at 1:1000 (fig 3a). Cancers (Basel) (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; rat; 1:200; loading ...; fig 5a
Abnova CD133 antibody (Abnova, PAB12663) was used in immunohistochemistry - paraffin section on rat samples at 1:200 (fig 5a). J Histochem Cytochem (2017) ncbi
domestic rabbit polyclonal
  • immunocytochemistry; domestic sheep; 1:500; fig 2i
In order to discuss the aggregative behavior and hair-inducing activity of ovine and human dermal papilla cells, Abnova CD133 antibody (Abnova, PAB12663) was used in immunocytochemistry on domestic sheep samples at 1:500 (fig 2i). Int J Trichology (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; fig 1
In order to investigate the role of sciellin in colorectal cancer, Abnova CD133 antibody (Abnova, PAB12663) was used in western blot on human samples (fig 1). Oncotarget (2016) ncbi
mouse monoclonal (487f5)
  • flow cytometry; human; fig 1
Abnova CD133 antibody (Abnova, MAB8818) was used in flow cytometry on human samples (fig 1). J Cell Biochem (2015) ncbi
Novus Biologicals
domestic rabbit polyclonal (19D759.2)
  • immunohistochemistry; human; 1:50; loading ...
Novus Biologicals CD133 antibody (Novus Biologicals, NB120-16518) was used in immunohistochemistry on human samples at 1:50. BMC Cancer (2021) ncbi
domestic rabbit polyclonal (19D759.2)
  • western blot; human; 1:500; loading ...; fig 6c
Novus Biologicals CD133 antibody (NOVUS, NB120-16518) was used in western blot on human samples at 1:500 (fig 6c). Cell Death Dis (2021) ncbi
domestic rabbit polyclonal (19D759.2)
  • immunoprecipitation; human; 1:2000; fig 1
Novus Biologicals CD133 antibody (Novus Biologicals, NB120-16518) was used in immunoprecipitation on human samples at 1:2000 (fig 1). Oncol Lett (2016) ncbi
domestic rabbit polyclonal (19D759.2)
  • immunohistochemistry; mouse; loading ...; fig s1b
In order to determine the function of CD24 using a mouse model of pancreatic ductal adenocarcinoma and cerulein-induced acute pancreatitis, Novus Biologicals CD133 antibody (Novus, NB120-16518) was used in immunohistochemistry on mouse samples (fig s1b). Oncotarget (2016) ncbi
Invitrogen
mouse monoclonal (TMP4)
  • immunohistochemistry - paraffin section; human; loading ...; fig 7a
  • flow cytometry; human; loading ...; fig 5a
Invitrogen CD133 antibody (eBioscience, 12-1338-42) was used in immunohistochemistry - paraffin section on human samples (fig 7a) and in flow cytometry on human samples (fig 5a). Oncotarget (2018) ncbi
domestic rabbit polyclonal
  • immunocytochemistry; rat; 1:100; loading ...
In order to compare the efficiency of fascaplysin with other drugs used to treat glial tumors, Invitrogen CD133 antibody (Invitrogen, PA5-38014) was used in immunocytochemistry on rat samples at 1:100. Oncol Lett (2017) ncbi
mouse monoclonal (5E3)
  • immunohistochemistry - paraffin section; mouse; 1:100; fig 9
In order to assess the effect of therapy with bone marrow-derived cells an atherosclerotic mouse model, Invitrogen CD133 antibody (Life Technologies, MA5-18323) was used in immunohistochemistry - paraffin section on mouse samples at 1:100 (fig 9). Biochem Cell Biol (2015) ncbi
MyBioSource
domestic rabbit polyclonal
  • flow cytometry; rat; loading ...
MyBioSource CD133 antibody (MyBioSource, MBS462020) was used in flow cytometry on rat samples . Stem Cell Res Ther (2021) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 1d
In order to investigate Rac1 activity and inhibition in gastric adenocarcinoma cells and mouse xenograft models for epithelial-to-mesenchymal transition and cancer stem-like cell phenotypes, MyBioSource CD133 antibody (MYBioSource, MBS462020) was used in western blot on human samples (fig 1d). Mol Cancer Res (2017) ncbi
OriGene
mouse monoclonal (EMK08)
  • immunohistochemistry; human; fig 1
OriGene CD133 antibody (Origene, TA309943) was used in immunohistochemistry on human samples (fig 1). PLoS ONE (2015) ncbi
Cell Signaling Technology
domestic rabbit monoclonal (D2V8Q)
  • western blot; human; loading ...; fig 3d
Cell Signaling Technology CD133 antibody (CST, 64326) was used in western blot on human samples (fig 3d). Cell Death Discov (2021) ncbi
domestic rabbit monoclonal (D2V8Q)
  • western blot; human; 1:1000; loading ...
Cell Signaling Technology CD133 antibody (Cell Signaling Technologies, 64326S) was used in western blot on human samples at 1:1000. Respir Res (2021) ncbi
domestic rabbit monoclonal (D2V8Q)
  • western blot; human; 1:1000; loading ...; fig 4i
Cell Signaling Technology CD133 antibody (CST, 64326) was used in western blot on human samples at 1:1000 (fig 4i). J Cancer (2021) ncbi
domestic rabbit monoclonal (D2V8Q)
  • immunohistochemistry - paraffin section; human; 1:1000; loading ...; fig 4g
Cell Signaling Technology CD133 antibody (CST, 64326) was used in immunohistochemistry - paraffin section on human samples at 1:1000 (fig 4g). Cancer Cell Int (2020) ncbi
domestic rabbit monoclonal (D2V8Q)
  • western blot; human; 1:1000; loading ...; fig 4e
Cell Signaling Technology CD133 antibody (CST, 64326) was used in western blot on human samples at 1:1000 (fig 4e). Cancer Cell Int (2020) ncbi
domestic rabbit monoclonal (D2V8Q)
  • western blot; human; loading ...; fig 3d
Cell Signaling Technology CD133 antibody (Cell Signaling Technology, 64326) was used in western blot on human samples (fig 3d). Aging (Albany NY) (2020) ncbi
domestic rabbit monoclonal (D2V8Q)
  • immunocytochemistry; human; loading ...; fig 1b
Cell Signaling Technology CD133 antibody (Cell Signaling, 64326) was used in immunocytochemistry on human samples (fig 1b). EBioMedicine (2019) ncbi
domestic rabbit monoclonal (A3G6K)
  • immunocytochemistry; human; 1:200; loading ...; fig 8b
  • western blot; human; 1:2000; loading ...; fig 5e
Cell Signaling Technology CD133 antibody (Cell Signaling, 3663) was used in immunocytochemistry on human samples at 1:200 (fig 8b) and in western blot on human samples at 1:2000 (fig 5e). Nat Cell Biol (2016) ncbi
domestic rabbit monoclonal (A3G6K)
  • western blot; human; loading ...; fig 2
Cell Signaling Technology CD133 antibody (Cell Signaling, 3663) was used in western blot on human samples (fig 2). Oncotarget (2015) ncbi
BD Biosciences
monoclonal (W6B3C1)
  • flow cytometry; human; loading ...; fig 2b
BD Biosciences CD133 antibody (BD Biosciences, 566593) was used in flow cytometry on human samples (fig 2b). Cell Death Dis (2021) ncbi
monoclonal (W6B3C1)
  • immunoprecipitation; human; 1:100; loading ...; fig 1c
BD Biosciences CD133 antibody (BD, 566593) was used in immunoprecipitation on human samples at 1:100 (fig 1c). Nat Neurosci (2019) ncbi
monoclonal (W6B3C1)
  • immunoprecipitation; human; 1:100; loading ...; fig 1c
BD Biosciences CD133 antibody (BD, 566593) was used in immunoprecipitation on human samples at 1:100 (fig 1c). Mob DNA (2018) ncbi
Articles Reviewed
  1. Chen Y, Lu C, Cheng W, Kuo K, Yu C, Ho H, et al. An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids. BMC Cancer. 2022;22:967 pubmed publisher
  2. Chao J, Feng L, Ye P, Chen X, Cui Q, Sun G, et al. Therapeutic development for Canavan disease using patient iPSCs introduced with the wild-type ASPA gene. iScience. 2022;25:104391 pubmed publisher
  3. Chen Y, Xu J, Pan W, Xu X, Ma X, Chu Y, et al. Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells. Thorac Cancer. 2022;13:1961-1973 pubmed publisher
  4. van der Heide V, Jangra S, Cohen P, Rathnasinghe R, Aslam S, Aydillo T, et al. Limited extent and consequences of pancreatic SARS-CoV-2 infection. Cell Rep. 2022;38:110508 pubmed publisher
  5. Passman A, Strauss R, McSpadden S, Finch Edmondson M, Andrewartha N, Woo K, et al. Maraviroc Prevents HCC Development by Suppressing Macrophages and the Liver Progenitor Cell Response in a Murine Chronic Liver Disease Model. Cancers (Basel). 2021;13: pubmed publisher
  6. Gyamfi J, Yeo J, Kwon D, Min B, Cha Y, Koo J, et al. Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer. NPJ Breast Cancer. 2021;7:129 pubmed publisher
  7. Ji Z, Chen S, Cui J, Huang W, Zhang R, Wei J, et al. Oct4-dependent FoxC1 activation improves the survival and neovascularization of mesenchymal stem cells under myocardial ischemia. Stem Cell Res Ther. 2021;12:483 pubmed publisher
  8. Gan G, Shi Z, Liu D, Zhang S, Zhu H, Wang Y, et al. 3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness. Cell Death Discov. 2021;7:173 pubmed publisher
  9. Enderle L, Shalaby K, Gorelik M, Weiss A, Blazer L, Paduch M, et al. A T cell redirection platform for co-targeting dual antigens on solid tumors. MAbs. 2021;13:1933690 pubmed publisher
  10. Pham Q, Taniyama D, Sekino Y, Akabane S, Babasaki T, Kobayashi G, et al. Clinicopathologic features of TDO2 overexpression in renal cell carcinoma. BMC Cancer. 2021;21:737 pubmed publisher
  11. Zhao Y, Li Z, Zhu Y, Fu J, Zhao X, Zhang Y, et al. Single-Cell Transcriptome Analysis Uncovers Intratumoral Heterogeneity and Underlying Mechanisms for Drug Resistance in Hepatobiliary Tumor Organoids. Adv Sci (Weinh). 2021;8:e2003897 pubmed publisher
  12. Zhao N, Wang F, Ahmed S, Liu K, Cathcart S, Dimaio D, et al. Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma. Front Oncol. 2021;11:616625 pubmed publisher
  13. Barthet V, Brucoli M, Ladds M, Nössing C, Kiourtis C, Baudot A, et al. Autophagy suppresses the formation of hepatocyte-derived cancer-initiating ductular progenitor cells in the liver. Sci Adv. 2021;7: pubmed publisher
  14. West J, Austin E, Rizzi E, Yan L, Tanjore H, Crabtree A, et al. KCNK3 Mutation Causes Altered Immune Function in Pulmonary Arterial Hypertension Patients and Mouse Models. Int J Mol Sci. 2021;22: pubmed publisher
  15. Wang P, Zhao L, Gong S, Xiong S, Wang J, Zou D, et al. HIF1α/HIF2α-Sox2/Klf4 promotes the malignant progression of glioblastoma via the EGFR-PI3K/AKT signalling pathway with positive feedback under hypoxia. Cell Death Dis. 2021;12:312 pubmed publisher
  16. Chioh F, Fong S, Young B, Wu K, Siau A, Krishnan S, et al. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. elife. 2021;10: pubmed publisher
  17. Knudsen A, Boldt H, Jakobsen E, Kristensen B. The multi-target small-molecule inhibitor SB747651A shows in vitro and in vivo anticancer efficacy in glioblastomas. Sci Rep. 2021;11:6066 pubmed publisher
  18. Shao N, Cheng J, Huang H, Gong X, Lu Y, Idris M, et al. GASC1 promotes hepatocellular carcinoma progression by inhibiting the degradation of ROCK2. Cell Death Dis. 2021;12:253 pubmed publisher
  19. Hao S, Zhu X, Liu Z, Wu X, Li S, Jiang P, et al. Chronic intermittent hypoxia promoted lung cancer stem cell-like properties via enhancing Bach1 expression. Respir Res. 2021;22:58 pubmed publisher
  20. Guo X, Liu L, Zhang Q, Yang W, Zhang Y. E2F7 Transcriptionally Inhibits MicroRNA-199b Expression to Promote USP47, Thereby Enhancing Colon Cancer Tumor Stem Cell Activity and Promoting the Occurrence of Colon Cancer. Front Oncol. 2020;10:565449 pubmed publisher
  21. Vavassori V, Mercuri E, Marcovecchio G, Castiello M, Schiroli G, Albano L, et al. Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome. EMBO Mol Med. 2021;13:e13545 pubmed publisher
  22. Ye D, Wang S, Huang Y, Wang X, Chi P. USP43 directly regulates ZEB1 protein, mediating proliferation and metastasis of colorectal cancer. J Cancer. 2021;12:404-416 pubmed publisher
  23. Huang F, Zheng C, Huang L, Lin C, Wang J. USP18 directly regulates Snail1 protein through ubiquitination pathway in colorectal cancer. Cancer Cell Int. 2020;20:346 pubmed publisher
  24. Leelatian N, Sinnaeve J, Mistry A, Barone S, Brockman A, Diggins K, et al. Unsupervised machine learning reveals risk stratifying glioblastoma tumor cells. elife. 2020;9: pubmed publisher
  25. Lin Z, Lin X, Zhu L, Huang J, Huang Y. TRIM2 directly deubiquitinates and stabilizes Snail1 protein, mediating proliferation and metastasis of lung adenocarcinoma. Cancer Cell Int. 2020;20:228 pubmed publisher
  26. Xu F, Liu Z, Liu R, Lu C, Wang L, Mao W, et al. Epigenetic induction of tumor stemness via the lipopolysaccharide-TET3-HOXB2 signaling axis in esophageal squamous cell carcinoma. Cell Commun Signal. 2020;18:17 pubmed publisher
  27. Wang R, Sharma R, Shen X, Laughney A, Funato K, Clark P, et al. Adult Human Glioblastomas Harbor Radial Glia-like Cells. Stem Cell Reports. 2020;14:338-350 pubmed publisher
  28. Lin L, Li Y, Liu M, Li Q, Liu Q, Li R. The Interleukin-33/ST2 axis promotes glioma mesenchymal transition, stemness and TMZ resistance via JNK activation. Aging (Albany NY). 2020;12:1685-1703 pubmed publisher
  29. Wang G, Xu J, Zhao J, Yin W, Liu D, Chen W, et al. Arf1-mediated lipid metabolism sustains cancer cells and its ablation induces anti-tumor immune responses in mice. Nat Commun. 2020;11:220 pubmed publisher
  30. Liu Y, Jiang Q, Liu X, Lin X, Tang Z, Liu C, et al. Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3β/β-catenin signaling pathway. EBioMedicine. 2019;48:386-404 pubmed publisher
  31. Veschi V, Mangiapane L, Nicotra A, Di Franco S, Scavo E, Apuzzo T, et al. Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant. Oncogene. 2020;39:987-1003 pubmed publisher
  32. Katsuda T, Matsuzaki J, Yamaguchi T, Yamada Y, Prieto Vila M, Hosaka K, et al. Generation of human hepatic progenitor cells with regenerative and metabolic capacities from primary hepatocytes. elife. 2019;8: pubmed publisher
  33. Vazquez Iglesias L, Barcia Castro L, Rodríguez Quiroga M, Páez de la Cadena M, Rodríguez Berrocal J, Cordero O. Surface expression marker profile in colon cancer cell lines and sphere-derived cells suggests complexity in CD26+ cancer stem cells subsets. Biol Open. 2019;8: pubmed publisher
  34. Wang R, Geng J, Sheng W, Liu X, Jiang M, Zhen Y. The ionophore antibiotic gramicidin A inhibits pancreatic cancer stem cells associated with CD47 down-regulation. Cancer Cell Int. 2019;19:145 pubmed publisher
  35. Cao J, Zhao M, Liu J, Zhang X, Pei Y, Wang J, et al. RACK1 Promotes Self-Renewal and Chemoresistance of Cancer Stem Cells in Human Hepatocellular Carcinoma through Stabilizing Nanog. Theranostics. 2019;9:811-828 pubmed publisher
  36. Wang J, Xu S, Duan J, Yi L, Guo Y, Shi Y, et al. Invasion of white matter tracts by glioma stem cells is regulated by a NOTCH1-SOX2 positive-feedback loop. Nat Neurosci. 2019;22:91-105 pubmed publisher
  37. Hu K, Li Y, Wu W, Chen H, Chen Z, Zhang Y, et al. High-performance gene expression and knockout tools using sleeping beauty transposon system. Mob DNA. 2018;9:33 pubmed publisher
  38. Huang W, Bei L, Eklund E. Inhibition of Fas associated phosphatase 1 (Fap1) facilitates apoptosis of colon cancer stem cells and enhances the effects of oxaliplatin. Oncotarget. 2018;9:25891-25902 pubmed publisher
  39. Osborn M, Lees C, McElroy A, Merkel S, Eide C, Mathews W, et al. CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. Int J Mol Sci. 2018;19: pubmed publisher
  40. Jung Y, Cackowski F, Yumoto K, Decker A, Wang J, Kim J, et al. CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. Cancer Res. 2018;78:2026-2039 pubmed publisher
  41. Hira V, Wormer J, Kakar H, Breznik B, van der Swaan B, Hulsbos R, et al. Periarteriolar Glioblastoma Stem Cell Niches Express Bone Marrow Hematopoietic Stem Cell Niche Proteins. J Histochem Cytochem. 2018;66:155-173 pubmed publisher
  42. Almasry S, Habib E, Elmansy R, Hassan Z. Hyperglycemia Alters the Protein Levels of Prominin-1 and VEGFA in the Retina of Albino Rats. J Histochem Cytochem. 2017;:22155417737484 pubmed publisher
  43. Ong D, Hu B, Ho Y, Sauvé C, Bristow C, Wang Q, et al. PAF promotes stemness and radioresistance of glioma stem cells. Proc Natl Acad Sci U S A. 2017;114:E9086-E9095 pubmed publisher
  44. Yoon C, Cho S, Chang K, Park D, Ryeom S, Yoon S. Role of Rac1 Pathway in Epithelial-to-Mesenchymal Transition and Cancer Stem-like Cell Phenotypes in Gastric Adenocarcinoma. Mol Cancer Res. 2017;15:1106-1116 pubmed publisher
  45. Gibier J, Hemon B, Fanchon M, Gaudelot K, Pottier N, Ringot B, et al. Dual role of MUC1 mucin in kidney ischemia-reperfusion injury: Nephroprotector in early phase, but pro-fibrotic in late phase. Biochim Biophys Acta Mol Basis Dis. 2017;1863:1336-1349 pubmed publisher
  46. Bryukhovetskiy I, Lyakhova I, Mischenko P, Milkina E, Zaitsev S, Khotimchenko Y, et al. Alkaloids of fascaplysin are effective conventional chemotherapeutic drugs, inhibiting the proliferation of C6 glioma cells and causing their death in vitro. Oncol Lett. 2017;13:738-746 pubmed publisher
  47. Lu X, Horner J, Paul E, Shang X, Troncoso P, Deng P, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543:728-732 pubmed publisher
  48. Vernot J, Bonilla X, Rodriguez Pardo V, Vanegas N. Phenotypic and Functional Alterations of Hematopoietic Stem and Progenitor Cells in an In Vitro Leukemia-Induced Microenvironment. Int J Mol Sci. 2017;18: pubmed publisher
  49. Zhang C, Mukherjee S, Tucker Burden C, Ross J, Chau M, Kong J, et al. TRIM8 regulates stemness in glioblastoma through PIAS3-STAT3. Mol Oncol. 2017;11:280-294 pubmed publisher
  50. Fromm J, Thomas A, Wood B. Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. Am J Pathol. 2017;187:304-317 pubmed publisher
  51. Sun H, Zhang M, Cheng K, Li P, Han S, Li R, et al. Resistance of glioma cells to nutrient-deprived microenvironment can be enhanced by CD133-mediated autophagy. Oncotarget. 2016;7:76238-76249 pubmed publisher
  52. Lee E, Wang J, Yumoto K, Jung Y, Cackowski F, Decker A, et al. DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis. Neoplasia. 2016;18:553-66 pubmed publisher
  53. Torres A, Vargas Y, Uribe D, Jaramillo C, Gleisner A, Salazar Onfray F, et al. Adenosine A3 receptor elicits chemoresistance mediated by multiple resistance-associated protein-1 in human glioblastoma stem-like cells. Oncotarget. 2016;7:67373-67386 pubmed publisher
  54. Sari A, Rufaut N, Jones L, Sinclair R. Characterization of Ovine Dermal Papilla Cell Aggregation. Int J Trichology. 2016;8:121-9 pubmed publisher
  55. Sousa A, Rei M, Freitas R, Ricardo S, Caffrey T, David L, et al. Effect of MUC1/?-catenin interaction on the tumorigenic capacity of pancreatic CD133+ cells. Oncol Lett. 2016;12:1811-1817 pubmed
  56. Zhou A, Lin K, Zhang S, Chen Y, Zhang N, Xue J, et al. Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. Nat Cell Biol. 2016;18:954-966 pubmed publisher
  57. Wang J, Liu X, Jiang Z, Li L, Cui Z, Gao Y, et al. A novel method to limit breast cancer stem cells in states of quiescence, proliferation or differentiation: Use of gel stress in combination with stem cell growth factors. Oncol Lett. 2016;12:1355-1360 pubmed
  58. Simile M, Latte G, Demartis M, Brozzetti S, Calvisi D, Porcu A, et al. Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease. Oncotarget. 2016;7:49194-49216 pubmed publisher
  59. Lubeseder Martellato C, Hidalgo Sastre A, Hartmann C, Alexandrow K, Kamyabi Moghaddam Z, Sipos B, et al. Membranous CD24 drives the epithelial phenotype of pancreatic cancer. Oncotarget. 2016;7:49156-49168 pubmed publisher
  60. Munthe S, Petterson S, Dahlrot R, Poulsen F, Hansen S, Kristensen B. Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype. PLoS ONE. 2016;11:e0155106 pubmed publisher
  61. Nel I, Gauler T, Bublitz K, Lazaridis L, Goergens A, Giebel B, et al. Circulating Tumor Cell Composition in Renal Cell Carcinoma. PLoS ONE. 2016;11:e0153018 pubmed publisher
  62. Garcia C, Videla Richardson G, Dimopoulos N, Fernandez Espinosa D, Miriuka S, Sevlever G, et al. Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199. PLoS ONE. 2016;11:e0152607 pubmed publisher
  63. Jung Y, Decker A, Wang J, Lee E, Kana L, Yumoto K, et al. Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. Oncotarget. 2016;7:25698-711 pubmed publisher
  64. Chou C, Fan C, Lin P, Liao P, Tung J, Hsieh C, et al. Sciellin mediates mesenchymal-to-epithelial transition in colorectal cancer hepatic metastasis. Oncotarget. 2016;7:25742-54 pubmed publisher
  65. Gradiz R, Silva H, Carvalho L, Botelho M, Mota Pinto A. MIA PaCa-2 and PANC-1 - pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors. Sci Rep. 2016;6:21648 pubmed publisher
  66. Fraveto A, Cardinale V, Bragazzi M, Giuliante F, De Rose A, Grazi G, et al. Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. PLoS ONE. 2015;10:e0142124 pubmed publisher
  67. Acikgoz E, Guven U, Duzagac F, Uslu R, Kara M, Soner B, et al. Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells. PLoS ONE. 2015;10:e0141090 pubmed publisher
  68. Sipos F, Constantinovits M, Valcz G, Tulassay Z, Műzes G. Association of hepatocyte-derived growth factor receptor/caudal type homeobox 2 co-expression with mucosal regeneration in active ulcerative colitis. World J Gastroenterol. 2015;21:8569-79 pubmed publisher
  69. Russell R, Perkhofer L, Liebau S, Lin Q, Lechel A, Feld F, et al. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. Nat Commun. 2015;6:7677 pubmed publisher
  70. Bongiorno Borbone L, Giacobbe A, Compagnone M, Eramo A, De Maria R, Peschiaroli A, et al. Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells. Oncotarget. 2015;6:16926-38 pubmed
  71. Felix A, Monteiro N, Rocha V, Oliveira G, Nascimento A, de Carvalho L, et al. Structural and ultrastructural evaluation of the aortic wall after transplantation of bone marrow-derived cells (BMCs) in a model for atherosclerosis. Biochem Cell Biol. 2015;93:367-75 pubmed publisher
  72. Ayadi M, Bouygues A, Ouaret D, Ferrand N, Chouaib S, Thiery J, et al. Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors. Oncotarget. 2015;6:18518-33 pubmed
  73. Cioffi M, D Alterio C, Camerlingo R, Tirino V, Consales C, Riccio A, et al. Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer. Sci Rep. 2015;5:10357 pubmed publisher
  74. Nunukova A, Neradil J, Skoda J, Jaroš J, Hampl A, Sterba J, et al. Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines. Int J Mol Med. 2015;36:65-72 pubmed publisher
  75. Flores Nascimento M, Aléssio A, de Andrade Orsi F, Annichino Bizzacchi J. CD144, CD146 and VEGFR-2 properly identify circulating endothelial cell. Rev Bras Hematol Hemoter. 2015;37:98-102 pubmed publisher
  76. Miconi G, Palumbo P, Dehcordi S, La Torre C, Lombardi F, Evtoski Z, et al. Immunophenotypic characterization of human glioblastoma stem cells: correlation with clinical outcome. J Cell Biochem. 2015;116:864-76 pubmed publisher
  77. Yamaguchi S, Maida Y, Yasukawa M, Kato T, Yoshida M, Masutomi K. Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells. PLoS ONE. 2014;9:e112438 pubmed publisher
  78. Chavali P, Saini R, Zhai Q, Vizlin Hodzic D, Venkatabalasubramanian S, Hayashi A, et al. TLX activates MMP-2, promotes self-renewal of tumor spheres in neuroblastoma and correlates with poor patient survival. Cell Death Dis. 2014;5:e1502 pubmed publisher
  79. Cucak H, Vistisen D, Witte D, Philipsen A, Rosendahl A. Reduction of specific circulating lymphocyte populations with metabolic risk factors in patients at risk to develop type 2 diabetes. PLoS ONE. 2014;9:e107140 pubmed publisher
  80. Holmberg Olausson K, Maire C, Haidar S, Ling J, Learner E, Nistér M, et al. Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas. PLoS ONE. 2014;9:e106694 pubmed publisher
  81. Wennerström A, Lothe I, Sandhu V, Kure E, Myklebost O, Munthe E. Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines. PLoS ONE. 2014;9:e103873 pubmed publisher
  82. Jeon H, Kim S, Jin X, Park J, Kim S, Joshi K, et al. Crosstalk between glioma-initiating cells and endothelial cells drives tumor progression. Cancer Res. 2014;74:4482-92 pubmed publisher
  83. Sahlberg S, Spiegelberg D, Glimelius B, Stenerlow B, Nestor M. Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. PLoS ONE. 2014;9:e94621 pubmed publisher
  84. Wang Z, Wang B, Shi Y, Xu C, Xiao H, Ma L, et al. Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. Oncogene. 2015;34:1407-19 pubmed publisher
  85. Huang A, Zhou H, Zhao H, Quan Y, Feng B, Zheng M. TMPRSS4 correlates with colorectal cancer pathological stage and regulates cell proliferation and self-renewal ability. Cancer Biol Ther. 2014;15:297-304 pubmed publisher
  86. Yu P, Yan M, Lai H, Huang R, Chou Y, Lin W, et al. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int J Cancer. 2014;134:542-51 pubmed publisher
  87. Denecke B, Horsch L, Radtke S, Fischer J, Horn P, Giebel B. Human endothelial colony-forming cells expanded with an improved protocol are a useful endothelial cell source for scaffold-based tissue engineering. J Tissue Eng Regen Med. 2015;9:E84-97 pubmed publisher